Introduction {#s1}
============

Polyhydramnios, an excess of amniotic fluid in the amniotic sac, is diagnosed if the single deepest pocket (SDP) is of ≥ 8 cm or the amniotic fluid index (AFI) is of ≥ 25 cm ([@B21]; [@B18]). It is present in 1--3% of pregnancies ([@B19]; [@B5]; [@B18]) and may occur as a consequence of both environmental (e.g., perinatal exposure to TORCH infections, maternal gestational and pregestational diabetes) and genetic factors ([@B3]; [@B12]; [@B28]; [@B13]; [@B14]). Indeed, a search for polyhydramnios in the Human Phenotype Ontology database (<https://hpo.jax.org/app/browse/term/HP:0001561>) yielded 204 different conditions and 143 different genes. Nearly one half of all pregnancies with polyhydramnios are associated with varying degrees of fetal abnormality, including fetal death ([@B14]). Therefore, it is extremely important to identify the genetic causes of polyhydramnios in affected families with a view to providing genetic counselling and prenatal diagnosis for subsequent pregnancies.

With the decreasing cost of next generation sequencing, whole exome sequencing (WES) has been increasingly employed as an important diagnostic tool for clinical purposes ([@B6]; [@B16]; [@B22]), especially in the case of diseases characterized by atypical manifestations and significant levels of genetic heterogeneity ([@B15]). Here we describe the use of WES to identify the genetic cause of polyhydramnios in two successive fetuses in a Chinese family.

Case Presentation {#s2}
=================

A 35-year-old woman was referred to our centre at the First Affiliated Hospital of Sun Yat-Sen University after her third fetus (II:3; [**Figure 1A**](#f1){ref-type="fig"}) had been found to have polyhydramnios (SDP of 9.5 cm and an AFI of 30.7 cm) and hydrocele of testis at 29 gestational weeks (GW). Prior to this, her second fetus (II:2) had presented with polyhydramnios and generalized edema (pleural effusion, ascites, skin edema of the chest, abdomen, and scalp) at 34 GW ([**Figures 2A--D**](#f2){ref-type="fig"}) and was then terminated at 36 GW. Her first child (II:1) is a healthy girl, now aged 6 years. Both parents were of south Chinese origin, healthy and non-consanguineous. Exposure to known mutagenic or teratogenic agents during pregnancy was not reported.

![Identification of the genetic basis of polyhydramnios in a Chinese family. **(A)** Family pedigree and DNA sequencing results. Filled triangle with oblique line indicates the fetus with polyhydramnios terminated by therapeutic abortion. Filled square with oblique line indicates the affected boy who died after birth. Arrow indicates the proband. Open symbols indicate clinically unaffected family members. *LMOD3* genotypes are provided for all subjects. Red arrows indicate the mutation positions. wt, wild-type. **(B)** Illustration of the LMOD3 structure and all currently reported severe NM-causing *LMOD3* variants. The two novel variants identified in the current study are highlighted in red. Previous reported variants (in black) were from ([@B32]; [@B4]; [@B20]). See [**Supplementary Table S1**](#SM1){ref-type="supplementary-material"} for variant descriptions at the nucleotide sequence level.](fgene-10-00835-g001){#f1}

![Ultrasound photographs of the 2 fetuses with polyhydramnios. **(A--E)** Ultrasound images of the first affected fetus (II-2) at 34 GW. Two-dimensional ultrasound showing polyhydramnios (amniotic fluid deep, AFD, 12.2 cm) **(A)** and fixed limbs **(E)**. Bilateral pleural effusion (**B**, yellow arrow), ascites (**C**, yellow arrow), skin edema of chest (**B**, white arrow), abdomen (**C**, white arrow), and scalp (**D**, white arrow) were detected by ultrasound. **(F, G)** Ultrasound pictures of the second affected nemaline myopathy fetus (II-3) at 33 GW. Two-dimensional ultrasound revealed polyhydramnios (amniotic fluid deep, AFD, 11.5cm) **(F)** and hydrocele of testis **(G)** (yellow arrow).](fgene-10-00835-g002){#f2}

In the case of II:2, only standard G-banding karyotyping (using cord blood cells taken at 35 GW) followed by chromosomal microarray analysis were performed at the time, yielding negative findings. In the case of fetus II:3, molecular genetic analysis including WES was performed at 31 GW. The WES results were returned to us 6 weeks later, confirming a diagnosis of nemaline myopathy (NM) (see below). Genetic counselling was provided to the couple, who opted to continue the pregnancy. The boy was born by full-term vaginal delivery at 37 GW; his Apgar scores were 5 and 6 (normal, 10) at 1 and 5 min of life, respectively. He showed stiffness of limbs, little movement and scrotal swelling, and died of respiratory failure 2 days after birth.

Clinical findings in the two affected fetuses (II:2 and II:3) are illustrated in [**Figure 2**](#f2){ref-type="fig"} and summarized in [**Table 1**](#T1){ref-type="table"}.

###### 

Summary of prenatal feature in 24 *LMOD3* mutation-positive cases of nemaline myopathy.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Case        Reference    Gender         Ethnicity   Polyhydramnios   Decreased fetal movements   Arthrogryposis/contracture   Fractures     Fetal edema            Other anomalies        Preterm delivery   Age at death (or current age if alive)   *LMOD3* genotype^†^
  ----------- ------------ -------------- ----------- ---------------- --------------------------- ---------------------------- ------------- ---------------------- ---------------------- ------------------ ---------------------------------------- ------------------------------------
  1           [@B32]       F              Algerian    \+               --                          \+                           \+            --                                            \+                 neonatal                                 p.S47fs\*13 homozygote

  2           M            Belgian        --          \+               \+                          --                           --                                   --                     10 months          p.S47fs\*13 homozygote                   

  3a          F            Portuguese     \+          \+               \+                          --                           --                                   --                     neonatal           p.M52\* homozygote                       

  3b          F            Portuguese     \+          --               \+                          --                           --                                   --                     1 months, alive                                             

  4           F            Japanese       \+          \+               --                          --                           --                                   --                     2 months, alive    p.\[T101Rfs\*4\]; \[D201Efs\*9\]         

  5           F            Japanese       \+          \+               \+                          --                           \+            Subdural hematoma      \+                     10 months, alive   p.Q117\* homozygote                      

  6           F            Japanese       \+          \+               --                          --                           --            microcephaly           --                     1 year, alive      p.\[Q117\*\]; \[K406Nfs\*11\]            

  7           F            Italian        \+          \+               \+                          --                           --                                   \+                     4 months           p.F287Sfs\*3 homozygote                  

  8           M            Ecuadorianmn   \+          \+               \+                          \+                           --                                   \+                     6 weeks            p.\[G326R\]; \[Q458\*\]                  

  9           M            Swedish        \+          --               \+                          --                           --                                   --                     5 months           p.E357\* homozygote                      

  10          M            Afghan         --          \+               \+                          --                           --                                   \+                     neonatal           p.N367Qfs\*11 homozygote                 

  11          M            Afghan         --          --               \+                          --                           --                                   \+                     2 months           p.N367Qfs\*11 homozygote                 

  12          F            Pakistani      \+          --               --                          --                           --                                   --                     3 months           p.N367Qfs\*11 homozygote                 

  13          F            Pakistani      \+          \+               --                          --                           --                                   --                     neonatal           p.N367Qfs\*11 homozygote                 

  14          F            Australian     \+          \+               --                          --                           --                                   --                     10 years, alive    p.\[N367del\]; \[R401\*\]                

  15          F            Australian     \+          --               --                          --                           --                                   --                     4 years, alive     p.\[N367del\]; \[R401\*\]                

  16a         [@B1]        F              Turkish     --               \+                          --                           \+            \+                                            \+                 neonatal                                 p.S47fs\*13 homozygote

  16b         F            Turkish        --          \+               --                          \+                           --                                   \+                     2 months                                                    

  16c         F            Turkish        \+          --               --                          \+                           \+                                   \+                     neonatal                                                    

  17          [@B4]        F              Moroccan    \+               \+                          \+                           --            --                                            NE                 induced abortion                         p.\[E121Rfs\*5\]; \[L245del\]

  18          [@B20]       F              Turkish     \+               \+                          \+                           --            \+                     atrial septum defect   --                 8 years, alive                           p.D295Rfs\*2 homozygote

  19          M            NE             \+          \+               \+                          --                           --            atrial septum defect   --                     5 months           p.E357\* homozygote                      

  20a         This study   Unknown        Chinese     \+               \+                          --                           --            \+                                            NE                 induced abortion                         p.\[G429Wfs\*35\]; \[K471Sfs\*18\]

  20b         M            Chinese        \+          \+               --                          --                           \+                                   --                     neonatal                                                    

  **Total**                                           **19/24**\       **17/24**\                  **13/24**\                   **5/24**\     **6/24**\                                     **9/22**\                                                   
                                                      **(79.2%)**      **(70.8%)**                 **(54.1%)**                  **(20.8%)**   **(25.0%)**                                   **(40.9%)**                                                 
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

+, present; --, absent; F, female; M, male; NE, not evaluated.

^†^See [**Supplementary Table S1**](#SM1){ref-type="supplementary-material"} for variant descriptions at the nucleotide sequence level.

Materials and Methods {#s3}
=====================

Subjects {#s3_1}
--------

This study was carried out in accordance with the recommendations of "ethical regulations of biomedical research involving humans, Ethics Committee of the First Hospital affiliated to Sun Yat-sen University" with written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by the "Ethics Committee of the First Hospital affiliated to Sun Yat-sen University". Prenatal diagnosis was undertaken through ultrasound-guided umbilical cord blood puncture in accordance with standard practice.

Karyotype and Chromosomal Microarray Analysis {#s3_2}
---------------------------------------------

Standard G-banding karyotyping was performed according to standard laboratory procedures. The chromosomal microarray experiments were conducted using the high-resolution Affymetrix CytoScan HD arrays (Affymetrix Inc., Santa Clara, CA) according to the manufacturer's protocols. Detected copy number variants were evaluated for clinical significance by comparing them with data in the scientific literature and publicly available databases: UCSC ([@B15]), DECIPHER database (<https://decipher.sanger.ac.uk/>), Database of Genomic Variants (DGV, <http://dgv.tcag.ca/dgv/app/home>), the International Standards for Cytogenomic Arrays (ISCA, <https://www.iscaconsortium.org/>), and Online Mendelian Inheritance in Man (OMIM, <https://www.omim.org/>). The results were then analyzed by the Chromosome Analysis Suite software version 3.3.0; the reporting threshold of copy number variants was set at 10 kb, with marker count at over 50, as previously reported ([@B31]).

Whole Exome Sequencing (WES) {#s3_3}
----------------------------

WES was performed in fetus II:3 and its parents. Genomic DNA was randomly fragmented and then purified by means of the magnetic particle method. Sequences were captured by Agilent SureSelect version 4 (Agilent Technologies, Santa Clara, CA) according to the manufacturer's protocols. After enrichment and purification, the DNA libraries were sequenced on a NextSeq500 sequencer following the manufacturer's instructions (Illumina, San Diego). The reads were aligned to hg19/GRCh37.p10 using the Burrows-Wheeler Aligner (version 0.59) ([@B17]). Base quality recalibration and local realignment of the Burrows-Wheeler aligned reads were then processed by means of GATK IndelRealigner (<https://software.broadinstitute.org/gatk/documentation/tooldocs/current/org_broadinstitute_gatk_tools_walkers_indels_IndelRealigner.php>) and GATK BaseRecalibrator (<https://software.broadinstitute.org/gatk/documentation/tooldocs/current/org_broadinstitute_gatk_tools_walkers_bqsr_BaseRecalibrator.php>), respectively. Single nucleotide variations and small indels were revealed by the GATK UnifiedGenotyper (<https://software.broadinstitute.org/gatk/documentation/tooldocs/current/org_broadinstitute_gatk_tools_walkers_genotyper_UnifiedGenotyper.php>). Variants were finally annotated employing the Consensus Coding Sequences Database at the National Centre for Biotechnology Information (<https://www.ncbi.nlm.nih.gov/CCDS/>).

Putative causal variants were sought in an unbiased and hypothesis-free manner. Trio sample strategy was applied to remove the bias that may arise by proband-only sequencing. Literature and population databases were used for variant annotation, including 1000 Genomes, dbSNP, GenomAD, Clinvar, HGMD, and OMIM. The synonymous and common SNPs (MAF \> 5%) were filtered out, and rare variants with high confidence were considered as disease-causing candidates for further genetic evaluation. Multiple computational algorithms were applied to assist the genetic evaluation of pathogenicity, including SIFT, Polyphen-2, and MutationTaster. Variants occurring in known phenotype-causing or -associated genes as well as in candidate genes selected on the basis of known biological, physiological or functional relevance to phenotype were considered with priority. The interpretation of variants was managed according to the American College of Medical Genetics (ACMG) guidelines.

Sanger Sequencing {#s3_4}
-----------------

All family members were subjected to Sanger sequencing of exon 2 of the *LMOD3* gene. PCR primers were designed by Oligo 6.0 (<http://www.oligo.net/downloads.html>). Primer sequences and PCR conditions are available upon request.

Reference Sequence and Variant Nomenclature
-------------------------------------------

NM_198271.4 was employed as the *LMOD3* mRNA reference sequence. Nomenclature for the description of *LMOD3* variants and genotypes followed the Human Genome Variation Society (HGVS) recommendations ([@B11]).

Currently Reported Variants in the *LMOD3* Gene {#s3_6}
-----------------------------------------------

Currently reported variants in the *LMOD3* gene were obtained from the Professional version of the Human Gene Mutation Database (HGMD; <https://www.qiagenbioinformatics.com/products/human-gene-mutation-database/>) ([@B26]) and augmented by a manual literature search.

Results {#s4}
=======

Karyotyping of fetus II:3 indicated the presence of a normal set of chromosomes. Chromosomal microarray analysis also failed to identify any pathogenic copy number variants. We then screened II:3 and his parents by WES to search for putative causal variants in an unbiased and hypothesis-free manner. Variants detected were then prioritized based on sequencing quality, allele frequency in the normal population, gene product damage potential, zygosity and mode of inheritance. The mean depth of coverage for the coding regions targeted with the WES was 267×. A mean of 99.2% of bases in the targeted coding regions were covered by at least 10 reads and 99.0% of bases in the targeted coding regions were covered by more than 20 reads. Compound heterozygous truncating variants, c.1283dupC (p.Gly429Trpfs\*35) and c.1412delA (p.Lys471Serfs\*18), were identified in exon 2 of the *LMOD3* gene (NM_0198272) in II:3; c.1283dupC was inherited from the mother whereas c.1412delA was inherited from the father ([**Figure 1A**](#f1){ref-type="fig"}). The genotypes in II:3 and his parents were confirmed by Sanger sequencing of exon 2 of the *LMOD3* gene. We also sequenced exon 2 of the *LMOD3* gene in II:1 and II:2. Neither variant was found in the former while both variants were found in the latter ([**Figure 1A**](#f1){ref-type="fig"}). Neither c.1283dupC nor c.1412delA have been previously described in the literature and are also absent from the Genome Aggregation Database (gnomAD, <http://gnomad.broadinstitute.org/>).

Homozygous or compound heterozygous variants (predominantly truncating and nonsense) in the *LMOD3* gene have recently been identified to be a cause of autosomal recessive NM ([@B32]). Our identification of novel compound heterozygous truncating variants in the *LMOD3* gene in the two fetuses with polyhydramnios therefore firmly established the diagnosis of NM.

All *LMOD3* variants so far reported to be causative for severe NM are illustrated in the context of the LMOD3 protein structure ([**Figure 1B**](#f1){ref-type="fig"}). The structure of LMOD3 is in accordance with [@B9], UniProt (<http://www.uniprot.org/>) and InterProScan 4 ([@B33]). Additionally, we collated prenatal features in all 22 known *LMOD3* mutation-positive severe NM cases ([**Table 1**](#T1){ref-type="table"}).

Discussion {#s5}
==========

Employing WES, we have successfully identified two novel compound heterozygous truncating variants, c.1283dupC and c.1412delA, in the *LMOD*3 gene in two successive fetuses from the same family with polyhydramnios. *LMOD3* encodes a member of the leiomodin family of proteins, leiomodin-3, which is localized to the pointed ends of thin filaments and acts as a catalyst of actin nucleation in skeletal and cardiac muscle where it is expressed ([@B10]; [@B9]; [@B23]; [@B7]; [@B29]; [@B8]). In 2014, [@B32] identified *LMOD3* as a new causative gene for autosomal recessive NM. NM is a disorder that is characterized by muscle dysfunction and electron-dense protein accumulations (nemaline bodies) in myofibers ([@B24]). Patients with mutations in *LMOD3* often present with a severe congenital form of early-onset generalized muscle weakness and hypotonia with respiratory insufficiency and feeding difficulties; they usually die in early infancy ([@B32]). NM is clinically and genetically heterogeneous, making it difficult to establish a correct diagnosis from clinical features alone. Fetuses with NM usually display decreased fetal movements and polyhydramnios without any particular disease-defining features. The identification of compound heterozygous *LMOD3* variants in our family therefore provided a definite diagnosis of the disease that could not otherwise have been made merely on the basis of clinical findings in the fetus.

To date, a total of 25 *LMOD3* variants have been reported in the literature ([**Supplementary Table S1**](#SM1){ref-type="supplementary-material"}). Of these, 4 missense variants, p.Arg83His, p.Glu142Asp, p.Lys282Glu, p.Pro552His, have been reported to cause Kleine-Levin syndrome ([@B2]); a further two missense variants, p.Leu550Phe and p.Gln335Arg, have been associated with a mild form of congenital NM ([@B25]) whereas a truncating variant, c.112delG (p.Glu38Lysfs\*15), has been detected in a case without a definite clinical diagnosis ([@B27]). By contrast, the remaining 18 variants (i.e., variants highlighted in black in [**Figure 1B**](#f1){ref-type="fig"}) were reported to be causative for severe NM ([@B32]; [@B1]; [@B4]; [@B20]). Notably, 83% (n = 15) of these latter 18 variants represent truncating variants (nonsense or frameshift). The addition of our two newly identified truncating variants increased this figure to 85% (17/20). Moreover, most previous studies analyzed patients with a diagnosis or suggestive diagnosis of NM ([@B32]). Only very recently have *LMOD3* variants been described in any detail in fetuses ([@B4]). Our study is the first to describe the prenatal and postnatal manifestations of *LMOD3*-related NM in the Chinese population.

LMOD3 contains three actin-binding domains, which are actin-binding helix \[A-h\], residues 69--79; leucine-rich repeat domain \[LLR\], residues 237--402; and Wiskott-Aldrich-syndrome protein homology 2 domain \[WH2\], residues 534--553 ([@B32]). It should be noted that 1 of our 2 novel *LMOD3* mutations, c.1412delA, led to the shortest C-terminal truncation among the *LMOD3* nonsense and frameshifting variants reported to date ([**Figure 1B**](#f1){ref-type="fig"}). This, together with the fact that c.1412delA is associated with a severe form of NM, serves to highlight the indispensable role of the WH2 domain in LMOD3 protein and function. Current models and *in vitro* assays support the view that the WH2 domain, an actin nucleator, stabilizes actin monomers in the trimer conformation, thereby promoting nucleation ([@B23]; [@B8]).

Finally, we evaluated the prenatal features of *LMOD3*-related severe NM reported elsewhere ([@B32]; [@B1]; [@B4]; [@B20]) as well as in this study. As shown in [**Table 1**](#T1){ref-type="table"}, the most frequently observed anomaly is polyhydramnios (79.2%), followed by decreased fetal movements (70.8%), arthrogryposis/contracture (54.1%), fetal edema (25.0%), and fractures (20.8%). This survey identified fetal edema, which has an even higher frequency than fracture ([@B1]), to be a new noteworthy feature of *LMOD3*-related severe NM in the fetal period. Fetal edema could be explained as follows: decreased fetal movement allows accumulation of subcutaneous fluid and causes subsequent atony in the diaphragm, leading to a change in thoracic pressure and a disturbance of lymphatic circulation ([@B30]). Taken together, we suggest that *LMOD3-*related severe NM should be considered in cases of prenatal diagnosis of fetal edema and polyhydramnios.

This is the first report of NM-causative *LMOD3* variants, and the first example of prenatal diagnosis of NM, in the Chinese population. The identification of a novel *LMOD3* variant (i.e., c.1412delA) generating the shortest LMOD3 truncation reported to date underscores the critical role of the WH2 domain in LMOD3 structure and function. Further, survey of the prenatal phenotypes of *LMOD3*-related severe NM identified fetal edema as a new presenting feature that may provide an early clue to facilitate prenatal diagnosis of the disease. Finally, we demonstrate once again the power of WES as an effective means to deliver a timely molecular diagnosis in a genetically and clinically highly heterogeneous disorder. We anticipate that the availability of genetic testing for NM will also allow clinicians to offer more reliable prognostic and recurrence risk information to families at risk.
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